Core Viewpoint - The company experienced a decline in revenue and profit during the reporting period due to industry cycles and intensified market competition, but it remains focused on core business, technological innovation, and market expansion to enhance competitiveness and improve service innovation [3][4]. Company Overview - The company did not change its controlling shareholder or actual controller during the reporting period [3]. - The company plans not to distribute cash dividends or issue bonus shares [2]. Financial Performance - In the first half of 2025, the company achieved revenue of 447,434,341.07 yuan and a net profit attributable to shareholders of -27,242,543.15 yuan, indicating a decline compared to the same period last year [3]. Business Development - The company launched the GENOisi? intelligent platform, leveraging AI in gene detection to enhance healthcare services [4][13]. - The company is advancing sequencing technology and has developed the Vega long-read sequencing platform in collaboration with PacBio, which has completed initial deliveries and testing [4][5]. - The NovaSeq 6000Dx-CN-BG sequencing instrument received medical device registration from the National Medical Products Administration (NMPA), marking a significant step towards domestic production capabilities [5]. Market Expansion - The company is expanding its overseas market presence for reproductive health and genetic disease detection products, with several products receiving EU CE certification [6][9]. - The company is conducting a multi-center prospective clinical cohort study in collaboration with over 30 institutions to optimize screening programs and promote clinical application [8]. Research and Development - The company has established partnerships with over 3,000 universities, research institutes, and hospitals, contributing to the publication of over 22,000 research papers [10]. - The company is enhancing its multi-omics product research and has optimized its Fiber-seq multi-omics solution to expand its applicability [10]. Laboratory Development - The company’s laboratories have achieved recognition from authoritative institutions, passing various quality evaluation projects and maintaining compliance with international standards [12]. AI Integration - The GENOisi? intelligent platform integrates AI to support clinical decision-making in disease prediction and diagnosis, marking a shift towards a collaborative clinical intelligence model [13][14]. - The BerryChat intelligent Q&A model has been successfully deployed in over a hundred medical institutions, enhancing the efficiency of clinical report processing [14].